المؤلفون: Sanchez-Salinas, Mario Andrés, Martín-López, Ana Á., Kwon, Mi, IACOBONI, GLORIA, Rejeski, Kai, Navarro Garces, Victor, Gallur, Laura, Cecilia del Carmen, Carpio Segura, Barba, Pere

المساهمون: Institut Català de la Salut, Iacoboni G, Sánchez‐Salinas MA, Gallur L, Carpio C, Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Rejeski k Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, Gene Center of the LMU Munich, Munich, Germany. Adult BMT and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Martín‐López AÁ Hematology Department, Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain. Centro de Investigación del Cáncer‐IBMCC, Salamanca, Spain. Kwon M Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain. Navarro V Oncology Data Science (ODySey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Avaluació de resultats (Assistència sanitària), Cèl·lules B - Tumors - Tractament, Cèl·lules T - Ús terapèutic, Medicaments antineoplàstics - Ús terapèutic, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse, Other subheadings::Other subheadings::Other subheadings::/drug therapy, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia

وصف الملف: application/pdf

العلاقة: HemaSphere;8(7); https://doi.org/10.1002/hem3.86Test; Iacoboni G, Sánchez-Salinas MA, Rejeski K, Martín-López AÁ, Kwon M, Navarro V, et al. Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells. HemaSphere. 2024 Jun 26;8(7):e86.; https://hdl.handle.net/11351/11672Test; 001255105500001

الإتاحة: https://doi.org/10.1002/hem3.86Test
https://hdl.handle.net/11351/11672Test

المؤلفون: Iraola, Josu, O'Reilly, Maeve, Menne, Tobias, IACOBONI, GLORIA, Navarro Garces, Victor, Barba, Pere, Abrisqueta, Pau, Kwon, Mi

المساهمون: Institut Català de la Salut, Iacoboni G, Barba P, Abrisqueta P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Iraola‐Truchuelo J Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. O’Reilly M Department of Hematology, University College London Hospitals, London, UK. Navarro V Oncology Data Science (ODySey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Menne T Department of Hematology, Freeman Hospital, Newcastle, UK. Kwon M Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Avaluació de resultats (Assistència sanitària), Cèl·lules T - Ús terapèutic, Cèl·lules B - Tumors - Tractament, Limfomes - Tractament, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse, Other subheadings::Other subheadings::Other subheadings::/drug therapy, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva

وصف الملف: application/pdf

العلاقة: HemaSphere;8(5); https://doi.org/10.1002/hem3.62Test; Iacoboni G, Iraola-Truchuelo J, O’Reilly M, Navarro V, Menne T, Kwon M, et al. Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy. HemaSphere. 2024 May 21;8(5):e62.; https://hdl.handle.net/11351/11604Test; 001228138800001

الإتاحة: https://doi.org/10.1002/hem3.62Test
https://hdl.handle.net/11351/11604Test

المؤلفون: Molinos-Quintana, Agueda, Alonso-Saladrigues, Anna, Herrero, Blanca, Caballero-Velazquez, Teresa, Galán-Gómez, Víctor, Panesso Romero, Melissa, Diaz de Heredia, Cristina

المساهمون: Institut Català de la Salut, Molinos-Quintana Á Pediatric Unit, Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain. Alonso-Saladrigues A CAR T-cell Unit. Leukemia and Lymphoma Department. Pediatric Cancer Center Barcelona (PCCB). Hospital Sant Joan de Déu de Barcelona, Barcelona, Spain. Herrero B Pediatric Hemato-Oncology Department, Peditric University Hospital del Niño Jesús, Madrid, Spain. Caballero-Velázquez T Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain. Galán-Gómez V Pediatric Hemato-Oncology Department, University Hospital La Paz, Institute for Health Research (IdiPAZ), Universidad Autónoma de Madrid, Madrid, Spain. Panesso M, Diaz-de-Heredia C Servei d'Hematologia i Oncologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Leucèmia limfoblàstica - Tractament, Cèl·lules T, Infants, DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Leukemia, Lymphoid::Precursor Cell Lymphoblastic Leukemia-Lymphoma::Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, NAMED GROUPS::Persons::Age Groups::Child, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::leucemia linfoide::leucemia-linfoma linfoblástico de células precursoras::leucemia-linfoma linfoblástico de células T precursoras, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::niño

وصف الملف: application/pdf

العلاقة: Frontiers in Immunology;14; https://doi.org/10.3389/fimmu.2023.1280580Test; Molinos-Quintana Á, Alonso-Saladrigues A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, et al. Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring. Front Immunol. 2024 Jan 16;14:1280580.; https://hdl.handle.net/11351/11066Test; 001153506000001

الإتاحة: https://doi.org/10.3389/fimmu.2023.1280580Test
https://hdl.handle.net/11351/11066Test

المؤلفون: Wang, Yucai, albanyan, omar, Munoz, Javier, Rejeski, Kai, SESQUES, Pierre, IACOBONI, GLORIA, Barba, Pere

المساهمون: Institut Català de la Salut, Rejeski K Department of Medicine III – Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany. Wang Y Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Albanyan O Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA. Munoz J Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, USA. Sesques P Hospices Civils de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, Pierre-Bénite, France. Iacoboni G Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Department of Medicine, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Limfomes - Tractament, Trastorns limfoproliferatius - Tractament, Cèl·lules T - Ús terapèutic - Efectes secundaris, DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, Mantle-Cell, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, Other subheadings::Other subheadings::Other subheadings::/adverse effects, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin::linfoma de células del manto, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos

وصف الملف: application/pdf

العلاقة: American Journal of Hematology;98(11); https://doi.org/10.1002/ajh.27056Test; Rejeski K, Wang Y, Albanyan O, Munoz J, Sesques P, Iacoboni G, et al. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. Am J Hematol. 2023 Nov;98(11):1699–710.; https://hdl.handle.net/11351/10464Test; 001051772500001

الإتاحة: https://doi.org/10.1002/ajh.27056Test
https://hdl.handle.net/11351/10464Test

المؤلفون: Perez, Ariel, Blumenberg , Viktoria, Bücklein, Veit, Völkl, Simon, Rejeski, Kai, IACOBONI, GLORIA, Barba, Pere

المساهمون: Institut Català de la Salut, Rejeski K, Blumenberg V, Bücklein VL Department of Medicine III – Hematology/Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK), Munich and Berlin sites, and German Cancer Research Center, Heidelberg, Germany. Bavarian Cancer Research Center (BZKF), partner sites, Munich and Erlangen, Germany. Perez A Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA. Blood and Marrow Transplant Program, Miami Cancer Institute, Miami, FL, USA. Iacoboni G, Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Völkl S Bavarian Cancer Research Center (BZKF), partner sites, Munich and Erlangen, Germany. Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Càncer, Immunoteràpia, Cèl·lules T, Antígens CD, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, Other subheadings::Other subheadings::Other subheadings::/adverse effects, DISEASES::Neoplasms, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos, ENFERMEDADES::neoplasias

وصف الملف: application/pdf

العلاقة: Science Advances;9(38); https://doi.org/10.1126/sciadv.adg3919Test; Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bücklein VL, Völkl S, et al. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Sci Adv. 2023 Sep 22;9(38):eadg3919.; https://hdl.handle.net/11351/10382Test

الإتاحة: https://doi.org/10.1126/sciadv.adg3919Test
https://hdl.handle.net/11351/10382Test

المؤلفون: Perez, Ariel, Jurinovic, Vindi, Holtick, Udo, Rejeski, Kai, IACOBONI, GLORIA, Bücklein, Veit

المساهمون: Institut Català de la Salut, Bücklein V Department of Medicine III, University Hospital, LMU Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. Perez A Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA. Blood and Marrow Transplant Program, Miami Cancer Institute, Miami, FL, USA. Rejeski K Department of Medicine III, University Hospital, LMU Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK) Munich Site, and German Cancer Research Center (DKFZ), Heidelberg, Germany. Iacoboni G Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Jurinovic V Institute for Medical Information Processing, Biometry, and Epidemiology, LMU Munich, Germany. Holtick U Department I of Internal Medicine, Medical Faculty and University Hospital, Cologne, University of Cologne, Germany, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Cèl·lules B - Tumors - Immunoteràpia, Avaluació de resultats (Assistència sanitària), DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell, Other subheadings::Other subheadings::/therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin::linfoma de células B, Otros calificadores::Otros calificadores::/terapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento

وصف الملف: application/pdf

العلاقة: HemaSphere;7(8); https://doi.org/10.1097/HS9.0000000000000907Test; Bücklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, et al. Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use. HemaSphere. 2023 Jul 11;7(8):e907.; https://hdl.handle.net/11351/10105Test; 001029914500001

الإتاحة: https://doi.org/10.1097/HS9.0000000000000907Test
https://hdl.handle.net/11351/10105Test

المؤلفون: Solano, Carlos, Castro Rebollo, Pedro, Pérez Martínez, Antonio, Lopez Corral, Lucia, Barba, Pere, Kwon, Mi

المساهمون: Institut Català de la Salut, Solano C Department of Hematology, Institute for Research (INCLIVA), Hospital Clínico Universitario, Valencia, Spain. School of Medicine, Department of Medicine, University of Valencia, Valencia, Spain. Castro-Rebollo P Medical Intensive Care Unit, Hospital Clinic de Barcelona, Barcelona, Spain. Pérez-Martínez A Pediatric Hemato-Oncology Department, La Paz University Hospital, Madrid, Spain. López-Corral L Hematology Service, Hospital Clínico Universitario de Salamanca, Salamanca, Spain. Barba-Suñol P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Kwon M Hematology Service, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Càncer - Tractament, Cèl·lules T - Ús terapèutic, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Artificial::Receptors, Chimeric Antigen, DISEASES::Neoplasms, Other subheadings::Other subheadings::/therapy, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores artificiales::receptores de antígenos quiméricos, ENFERMEDADES::neoplasias, Otros calificadores::Otros calificadores::/terapia

وصف الملف: application/pdf

العلاقة: BMJ Open;13(7); http://dx.doi.org/10.1136/bmjopen-2022-071371Test; Solano C, Castro-Rebollo P, Pérez-Martínez A, López-Corral L, Barba-Suñol P, Kwon M, et al. Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study. BMJ Open. 2023 Jul 25;13(7):e071371.; https://hdl.handle.net/11351/10150Test

الإتاحة: https://doi.org/10.1136/bmjopen-2022-071371Test
https://hdl.handle.net/11351/10150Test

المؤلفون: Palomba, M. Lia, Ghione, Paola, Patel, Anik R., Nahas, Myrna, Beygi, Sara, Hatswell, Anthony, Bobillo Varela, Sabela

المساهمون: Institut Català de la Salut, Palomba ML, Ghione P Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Patel AR, Nahas M, Beygi S Kite, A Gilead Company, Santa Monica, CA, USA. Hatswell AJ Delta Hat, Nottingham, UK. Bobillo S Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Avaluació de resultats (Assistència sanitària), Limfomes - Immunoteràpia, Cèl·lules B - Tumors - Immunoteràpia, DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, Follicular, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin::linfoma folicular, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento

وصف الملف: application/pdf

العلاقة: Expert Review of Anticancer Therapy;23(2); https://doi.org/10.1080/14737140.2023.2171994Test; Palomba L, Ghione P, Patel AR, Nahas M, Beygi S, Hatswell AJ, et al. A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Expert Rev Anticancer Ther. 2023 Feb;23(2):199–206.; https://hdl.handle.net/11351/9115Test

الإتاحة: https://doi.org/10.1080/14737140.2023.2171994Test
https://hdl.handle.net/11351/9115Test

المؤلفون: Perez, Ariel, Iacoboni García-Calvo, Gloria, Penack, Olaf, Jentzsch, Liv, Carpio Segura, Cecilia Carmen, Barba Suñol, Pere, Rejeski, Kai, Bücklein, Veit

المساهمون: Institut Català de la Salut, Rejeski K Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK) Munich Site, and German Cancer Research Center, Heidelberg, Germany. Perez A Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA. Blood & Marrow Transplant Program, Miami Cancer Institute, Miami, Florida, USA. Iacoboni G, Carpio C, Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma of Barcelona, Bellaterra, Spain. Penack O Department of Hematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. German Cancer Consortium (DKTK) Berlin Site, and German Cancer Research Center, Heidelberg, Germany. Bücklein V Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. Jentzsch L Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Cèl·lules B - Tumors - Tractament, Immunoteràpia, Antígens CD - Immunologia, DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse, Other subheadings::Other subheadings::/therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, CHEMICALS AND DRUGS::Biological Factors::Antigens::Antigens, Surface::Antigens, Differentiation::Antigens, CD::Antigens, CD19, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso, Otros calificadores::Otros calificadores::/terapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::antígenos::antígenos de superficie::antígenos de diferenciación::antígenos CD::antígenos CD19

وصف الملف: application/pdf

العلاقة: Journal for ImmunoTherapy of Cancer;10(5); http://dx.doi.org/10.1136/jitc-2021-004475Test; Rejeski K, Perez A, Iacoboni G, Penack O, Bücklein V, Jentzsch L, et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. J Immunother Cancer. 2022 May;10(5):e004475.; https://hdl.handle.net/11351/8036Test; 000797594100008

الإتاحة: https://doi.org/10.1136/jitc-2021-004475Test
https://hdl.handle.net/11351/8036Test

المؤلفون: Busca, Alessandro, Salmanton-García, Jon, Corradini, Paolo, Di Blasi, Roberta, Marchesi, Francesco, Cabirta, Alba

المساهمون: Institut Català de la Salut, Busca A Stem Cell Transplant Center, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin, Italy. Salmanton-García J Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Faculty of Medicine and University Hospital Cologne, Cologne, Germany. Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University Hospital Cologne, Cologne, Germany. Corradini P University of Milan and Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy. Marchesi F Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. Cabirta A Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Di Blasi R Hôpital Saint Louis, Assistance Publique–Hopitaux de Paris (AP-HP), Paris, France, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Cèl·lules T, Teràpia cel·lular, COVID-19 (Malaltia), DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections, ANATOMY::Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus, ANATOMÍA::células::células sanguíneas::leucocitos::leucocitos mononucleares::linfocitos::linfocitos T, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva

وصف الملف: application/pdf

العلاقة: Blood Advances;6(7); https://doi.org/10.1182/bloodadvances.2021005616Test; Busca A, Salmanton-Garcıa J, Corradini P, Marchesi F, Cabirta A, Blasi R Di, et al. COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. Blood Adv. 2022 Apr 12;6(7):2427–33.; https://hdl.handle.net/11351/9565Test

الإتاحة: https://doi.org/10.1182/bloodadvances.2021005616Test
https://hdl.handle.net/11351/9565Test